AP2011005707A0 - Inclusion complexes of pinocembrin with cyclodextrin or its derivatives. - Google Patents

Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.

Info

Publication number
AP2011005707A0
AP2011005707A0 AP2011005707A AP2011005707A AP2011005707A0 AP 2011005707 A0 AP2011005707 A0 AP 2011005707A0 AP 2011005707 A AP2011005707 A AP 2011005707A AP 2011005707 A AP2011005707 A AP 2011005707A AP 2011005707 A0 AP2011005707 A0 AP 2011005707A0
Authority
AP
ARIPO
Prior art keywords
pinocembrin
cyclodextrin
derivatives
inclusion complexes
complexes
Prior art date
Application number
AP2011005707A
Other languages
English (en)
Inventor
Yan Qi
Song Wu
Guanhua Du
Original Assignee
Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Inst Materia Medica Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd, Inst Materia Medica Cams filed Critical Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd
Publication of AP2011005707A0 publication Critical patent/AP2011005707A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AP2011005707A 2008-11-11 2008-11-11 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives. AP2011005707A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2008/073011 WO2010054507A1 (zh) 2008-11-11 2008-11-11 松属素环糊精或环糊精衍生物包合物

Publications (1)

Publication Number Publication Date
AP2011005707A0 true AP2011005707A0 (en) 2011-06-30

Family

ID=42169585

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2011005707A AP2011005707A0 (en) 2008-11-11 2008-11-11 Inclusion complexes of pinocembrin with cyclodextrin or its derivatives.

Country Status (16)

Country Link
US (1) US9949946B2 (pt)
EP (1) EP2359861B1 (pt)
JP (1) JP5413998B2 (pt)
KR (1) KR101563308B1 (pt)
AP (1) AP2011005707A0 (pt)
AU (1) AU2008364165B2 (pt)
BR (1) BRPI0823254A2 (pt)
CA (1) CA2743006C (pt)
CU (1) CU24034B1 (pt)
EA (1) EA020784B1 (pt)
ES (1) ES2438294T3 (pt)
IL (2) IL212819A (pt)
MX (1) MX2011004991A (pt)
UA (1) UA99979C2 (pt)
WO (1) WO2010054507A1 (pt)
ZA (1) ZA201103244B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377529A4 (en) * 2008-12-11 2013-05-22 Cspc Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd USE OF RACEMATES OF PINOCEMBRIN IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF STROKE
GR1007520B (el) * 2010-12-02 2012-02-02 Apivita - Καλλυντικα - Διαιτητικα - Φαρμακα Ανωνυμη Εμπορικη Και Βιοτεχνικη Εταιρεια, Ταυτοχρονη εκχυλιση και σχηματισμος συμπλοκων εγκλεισμου των δραστικων συστατικων της προπολης με υδροξυπροπυλο-β-κυκλοδεξτρινη
CN104270945B (zh) 2012-03-19 2017-03-29 巴克老龄化研究所 App特异性bace抑制剂(asbi)及其用途
CA2899938C (en) 2013-02-12 2021-10-19 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
GB2584009B (en) 2017-08-28 2022-03-23 Revagenix Inc Aminoglycosides and uses thereof
WO2019194858A1 (en) 2018-04-03 2019-10-10 Achaogen, Inc. Modular synthesis of aminoglycosides
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도
CN119522229A (zh) 2022-03-04 2025-02-25 瑞瓦吉尼克斯股份有限公司 广谱氨基糖苷及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8904296D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
JP3269737B2 (ja) * 1994-08-31 2002-04-02 宇野醤油株式会社 食品保存料、およびその製造方法
JP2782335B2 (ja) 1996-03-04 1998-07-30 株式会社武田薬化学研究所 プロポリスの水分散液
CN1424112A (zh) 2002-12-17 2003-06-18 上海医药工业研究院 难溶性药物的水溶性包合物及其制备方法
CN1285334C (zh) 2004-05-12 2006-11-22 中国医学科学院药物研究所 生松素在制备防治神经细胞损伤相关疾病药物中的应用
EP1771149A1 (en) * 2004-07-23 2007-04-11 The Procter and Gamble Company Skin care composition containing a flavonoid and vitamin b3
CN1739537A (zh) 2004-08-26 2006-03-01 张红军 灯盏花素环糊精包合物及其制剂
KR100601395B1 (ko) 2004-11-04 2006-07-18 한국식품연구원 수용성 프로폴리스 추출물 및 분말의 제조 방법
CN1311815C (zh) 2005-05-08 2007-04-25 浙江大学 亚微米蜂胶微胶囊的制备方法
CN1879656B (zh) * 2006-04-27 2010-04-21 魏春华 固体水溶性蜂胶组合物及其制备方法

Also Published As

Publication number Publication date
US9949946B2 (en) 2018-04-24
JP2012508191A (ja) 2012-04-05
IL212819A (en) 2015-07-30
JP5413998B2 (ja) 2014-02-12
ZA201103244B (en) 2011-12-28
UA99979C2 (uk) 2012-10-25
IL212819A0 (en) 2011-07-31
CU24034B1 (es) 2014-10-02
EP2359861A4 (en) 2012-05-02
US20110218173A1 (en) 2011-09-08
EA201100730A1 (ru) 2011-10-31
EA020784B1 (ru) 2015-01-30
HK1155094A1 (en) 2012-08-03
BRPI0823254A2 (pt) 2015-06-23
CA2743006A1 (en) 2010-05-20
KR101563308B1 (ko) 2015-10-26
CU20110103A7 (es) 2012-01-31
EP2359861A1 (en) 2011-08-24
KR20110098906A (ko) 2011-09-02
EP2359861B1 (en) 2013-09-11
AU2008364165B2 (en) 2015-01-29
WO2010054507A1 (zh) 2010-05-20
ES2438294T3 (es) 2014-01-16
AU2008364165A1 (en) 2010-05-20
CA2743006C (en) 2016-02-09
MX2011004991A (es) 2011-07-29

Similar Documents

Publication Publication Date Title
AP2012006216A0 (en) Benzimidazole-imidazole derivatives.
BRPI0906611A2 (pt) Produtos implantáveis compreendendo nanopartículas.
IL212819A0 (en) Inclusion complexes of pinocembrin with cyclodextrin or its derivatives
AP2012006167A0 (en) DLL4-binding molecules.
ZA201104540B (en) Usirna complexes
IL210548A0 (en) Spiroaminodihydrothiazine derivatives
ZA201100799B (en) Imidazopyridin-2-one derivatives
ZA201003752B (en) Phthalazinone derivatives
SG10201506608RA (en) 3-deazaneplanocin derivatives
ZA201100876B (en) Pyrrolopyridinylpyrimidin-2-ylamine derivatives
ZA201102449B (en) Morpholinopurine derivatives
BRPI1016117A2 (pt) derivados de isoxazol-isoxazol e isoxasol-isotiazol.
IL210592A0 (en) Novel substituted sulfamide derivatives
IL208336A0 (en) Pyrisazinone derivatives
IL210869A0 (en) Imidazothiadiazoles derivatives
EP2322365A4 (en) CROSSBOX INTEGRATED TAP STORAGE
BRPI0917446A2 (pt) derivados de acilaminobenzamida.
IL208065A0 (en) Glucopyranoside derivatives
IL210164A0 (en) Thiazolylpiperidine derivatives
IL213424A0 (en) Quinazolinamide derivatives
ZA201005382B (en) Substituted heteroarylamide diazepinopyrimidone derivatives
IL207191A0 (en) Substituted heteroaylamide oxazepyrimidone derivatives
ZA201008052B (en) 2-phenyl-4-cyclopropyl-pyrimidine derivatives
BRPI1016192A2 (pt) derivados de soxazol.
DK2442870T3 (da) Pyrazinooxazepin-derivater.